IDEA Biosciences filed its first rolling NDA for derovacertib in the third quarter and anticipates acceptance in the first half of next year. It plans to start two registrational phase three studies by the end of the year.
IDYA · IDEAYA Biosciences, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
IDEAYA Biosciences submitted an NDA to the FDA for the darovasertib combination in metastatic uveal melanoma, stopped enrollment in OptimUM-010, and reported approximately $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026.
IDEAYA Biosciences completed its darovasertib NDA submission, stopped enrollment in OptimUM-010 to save $100-125 million, and reported a $125.7 million net loss with $1.15 billion in cash and marketable securities at September 30, 2026.